XML 22 R12.htm IDEA: XBRL DOCUMENT
v3.20.4

Share-Based Payments | 9 Months Ended
--- | ---
Jan. 31, 2021
Share-based Payment Arrangement [Abstract] |
Share-Based Payments | Share-Based Payments The Company has in place a 2010 Equity Incentive Plan and a 2008 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. Stock-based compensation expense was recognized as follows (table in thousands):
| Three Months Ended January 31, |  | Nine Months Ended January 31, |  |
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |  |  |
General and administrative | $ | 149 |  |  | $ | 110 |  |  | $ | 206 |  |  | $ | 281 |  |  |  |  |
Sales and marketing | 51 |  |  | 95 |  |  | 148 |  |  | 144 |  |  |  |  |
Research and development | 7 |  |  | 4 |  |  | 16 |  |  | 9 |  |  |  |  |
Cost of oncology services | 25 |  |  | 20 |  |  | 67 |  |  | 3 |  |  |  |  |
Total stock-based compensation expense | $ | 232 |  |  | $ | 229 |  |  | $ | 437 |  |  | $ | 437 |  |  |  |  |
Stock Option Grants Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2021 and 2020 were as follows:
| Three Months Ended January 31, |  | Nine Months Ended January 31, |  |
| 2021 |  | 2020 |  | 2021 |  | 2020 |  |  |  |
Expected term in years | 3 |  | 3-6 |  | 3-6 |  | 3-6 |  |  |  |
Risk-free interest rates | 0.12% |  | 1.57%-1.80% |  | 0.12%-0.39% |  | 1.57%-1.80% |  |  |  |
Volatility | 74.98% |  | 69.14%-70.99% |  | 72.64%-74.98% |  | 69.14%-71.11% |  |  |  |
Dividend yield | —% |  | —% |  | —% |  | —% |  |  |  |
The weighted average fair value of stock options granted during the three months ended January 31, 2021 and 2020 was $5.80 and $2.56, respectively, and $5.08 and $3.09 for the nine months ended January 31, 2021 and 2020, respectively. The Company’s stock options activity for the nine months ended January 31, 2021 was a s follows:
| Directors and Employees | Non- Employees |  |  | Total |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (Years) |  | Aggregate Intrinsic Value
Outstanding, April 30, 2020 | 2,228,326 |  | 43,332 |  |  |  | 2,271,658 |  |  | $ | 3.23 |  |  | 5.0 |  | $ | 10,663,000 |
Granted | 133,833 |  | — |  |  |  | 133,833 |  |  | 9.21 |  |  | 7.58 |  |
Exercised | (662,285) |  | (1,159) |  |  |  | (663,444) |  |  | 2.27 |  |  |  |  |
Forfeited | (7,000) |  | — |  |  |  | (7,000) |  |  | 6.43 |  |  |  |  |
Canceled | (34,978) |  | (923) |  |  |  | (35,901) |  |  | 4.03 |  |  |  |  |
Expired | — |  | (5,834) |  |  |  | (5,834) |  |  | 10.80 |  |  |  |  |
Outstanding, January 31, 2021 | 1,657,896 |  | 35,416 |  |  |  | 1,693,312 |  |  | 4.02 |  |  | 5.66 |  | $ | 11,975,000 |
Vested and expected to vest as of January 31, 2021 | 1,657,896 |  | 35,416 |  |  |  | 1,693,312 |  |  | 4.02 |  |  | 5.66 |  | $ | 11,975,000 |
Exercisable as of January 31, 2021 | 1,289,104 |  | 9,584 |  |  |  | 1,298,688 |  |  | 3.25 |  |  | 4.93 |  | $ | 10,173,000 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration